The most common side effects include conjunctival hyperaemia (red eye), pain at the site where the medicine was applied, cornea verticillata (deposits in the cornea, the transparent layer in front of the eye that covers the pupil and iris), pruritus (itching of the eye), erythema (reddening) and discomfort in the eye, increased lacrimation (watery eyes), and conjunctival haemorrhage (bleeding in the surface layer of the eye).[2]
Netarsudil/latanoprost was approved for medical use in the United States in March 2019,[4] and in the European Union in January 2021.[2]
Netarsudil/latanoprost is indicated for the reduction of elevated intraocular pressure (IOP) in adults with primary open-angle glaucoma or ocular hypertension.[1][2]
^ abcdefg"Roclanda EPAR". European Medicines Agency (EMA). 9 November 2020. Retrieved 22 January 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
